Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259789 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT03259789 is a Phase 3 study that has completed, run by Theracos. The registered enrollment target is 351 participants.
The verdict
NCT03259789, a Phase 3 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Bexagliflozin tablets, placebo
- DRUG Bexagliflozin tablets, 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259789
The ClinicalTrials.gov registry entry for NCT03259789 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bexagliflozin tablets, placebo is the first listed.
NCT03259789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259789 about?
NCT03259789 is a clinical study titled "Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects". The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT03259789?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2017-11-28. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT03259789?
The interventions under investigation include: Bexagliflozin tablets, placebo (DRUG), Bexagliflozin tablets, 20 mg (DRUG).
Who is sponsoring clinical trial NCT03259789?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.